Euroapi S.A.·Healthcare

Press Release Paris – May 13, 2026 – EUROAPI takes note of local media reports regarding its Brindisi site. As previously communicated, the review of strategic options for certain industrial assets is progressing in line with the Group's FOCUS-27 transformation plan, with the objective of completing the related processes by the end of 2027.

Press Release Availability of the 2025 Universal Registration Document, including the Annual Financial Report Paris – March 27, 2026 – EUROAPI announces the publication of its 2025 Universal Registration Document in ESEF format, filed with the French Autorité des marchés financiers (AMF) on March 27, 2026. The 2025 Universal Registration Document contains in particular: The annual financial report, including the management report that encompasses namely the Corporate Governance report, the sustainability statement and the company and consolidated statements; The statutory auditors' reports, including the special report on the regulated agreements; The disclosures relating to statutory auditors' fees; and The disclosures relating to the description of the share buy-back program.

Euroapi S.A. (EAPIF) Q4 2025 Earnings Call Transcript
Euroapi SA develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. The company was incorporated in 2021 and is based in Paris, France.
Healthcare
Medical - Devices
3,187
2022-05-20
0.96